A murine monoclonal antibody (MAb F-91-55) raised against the complex of soluble CD4 and human immunodeficiency virus type 1 (HIV-1) gp120 had previously been found to inhibit syncytium formation without inhibiting the interaction of CD4 with gp120, and its binding site was localized within the first two domains (D1/D2) of CD4. We investigated whether this antibody inhibited the infectivity of HIV-1 in the CD4+ T cell lines A3.01, Sup-T1 and H9. We also examined the effect of the antibody on syncytium formation between these cells and chronically infected H9 cells. Syncytium formation was found to depend critically on the incubation medium used. The effect of the MAb on HIV-1 infectivity was very limited with A3.01 and Sup-T1 cells, although it inhibited syncytium formation between A3.01 or Sup-T1 and chronically infected H9 cells. In contrast, the MAb inhibited significantly the infectivity of HIV-1 in H9 cells, but it also inhibited syncytium formation between H9 and chronically infected H9 cells to a greater extent than in the case of the other cell lines. Our results indicate that cellular systems used for syncytium assays differ in their susceptibility to inhibitory antibodies. In the A3.01 and Sup-T1 cell systems, the differences in the ability of the MAb to block viral entry or syncytium formation raise the possibility that the mechanisms of interaction of gp120/gp41 with cell membrane CD4 may be different in cell-cell and virus-cell membrane fusion.
BenkiraneM.,
CorbeauP.,
HoussetV.,
DevauxC.1993; An antibody that binds the immunoglobulin CDR3-like region of the CD4 molecule inhibits provirus transcription in HIV-infected cells. EM BO Journal 12:4909–4921
BroderC. C.,
BergerE. A.1993; CD4 molecules with a diversity of mutations encompassing the CDR3 region efficiently support human immunodeficiency virus type 1 envelope glycoprotein-mediated cell fusion. Journal of Virology 67:913–926
BurklyL. C.,
OlsonD.,
ShapiroR.,
WinklerG.,
RosaJ. J.,
ThomasD. W.,
WilliamsC.,
ChisholmP.1992; Inhibition of HIV infection by a novel CD4 domain 2-specific monoclonal antibody. Dissecting the basis for its inhibitory effect on HIV-induced cell fusion. Journal of Immunology 149:1779–1787
CaoJ.,
BergeronL.,
HelsethE.,
ThaliM.,
RepkeH.,
SodroskiJ.1993; Effects of amino acid changes in the extracellular domain of the human immunodeficiency virus type 1 gp41 envelope glycoprotein. Journal of Virology 67:2747–2755
CorbeauP.,
BenkiraneM.,
WeilR.,
DavidC.,
EmilianiS.,
OliveD.,
MawasC.,
SerreA.,
DevauxC.1993; Ig CDR3-like region of the CD4 molecule is involved in HIV-induced syncytia formation but not in viral entry. Journal of Immunology 150:290–301
CorbeauP.,
HaranM.,
BinzH.,
DevauxC.1994; Jacalin, a lectin with anti-HIV-1 properties, and HIV-1 gp120 envelope protein interact with distinct regions of the CD4 molecule. Molecular Immunology 31:569–575
DaarE. S.,
LiX. L.,
MoudgilT.,
HoD. D.1990; High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proceedings of the National Academy of Sciences, USA 87:6574–6578
DalgleishA. G.,
BeverlyC. L.,
ClaphamP. R.,
CrawfordM.,
GreavesF.,
WeissR. A.1984; The CD4 (T4) antigen is an essential component of the receptor for AIDS retrovirus. Nature 312:763–767
De JongJ. J.,
GoudsmitJ.,
KeulenW.,
KlaverB.,
KroneW.,
TersmetteM.,
De RondeA.1992; Human immunodeficiency virus type 1 clones chimeric for the envelope V3 domain differ in syncytium formation and replication capacity. Journal of Virology 66:757–765
DimitrovD. S.,
BroderC. C.,
BergerE. A.,
BlumenthalR.1993; Calcium ions are required for cell fusion mediated by the CD4-human immunodeficiency virus type 1 envelope glycoprotein interaction. Journal of Virology 67:1647–1652
FaveroJ.,
CorbeauP.,
NicolasM.,
BenkiraneM.,
TravéG.,
DixonJ. F. P.,
AucouturierP.,
RasheedS.,
ParkerJ. W.,
LiautardJ. P.,
DevauxC.,
DornandJ.1993; Inhibition of human immunodeficiency virus infection by the lectin jacalin and by a derived peptide showing a sequence similarity with gp120. European Journal of Immunology 23:179–185
GershoniJ. M.,
DenisovaG.,
RavivD.,
SmorodinskyN. I.,
BuyanerD.1993; HIV binding to its receptor creates specific epitopes for the CD4/gp120 complex. FASEB Journal 7:1185–1187
GoldingH.,
BlumenthalR.,
ManischewitzJ.,
LittmanD. R.,
DimitrovD. S.1993; Cell fusion mediated by interaction of a hybrid CD4.CD8 molecule with the human immunodeficiency virus type 1 envelope glycoprotein does occur after a long lag time. Journal of Virology 67:6469–6475
HasanumaT.,
TsubotaH. S.,
WatanabeM.,
ChenZ. W.,
LordC. I.,
BurklyL. C.,
DaleyJ. F.,
LetvinN. L.1992; Regions of the CD4 molecule not involved in virus binding or syncytia formation are required for HIV-1 infction of lymphocytes. Journal of Immunology 148:1841–1846
HealeyD.,
DiandaL.,
MooreJ. P.,
McDougalJ. S.,
MooreM. J.,
EstessP.,
BuckD.,
KwongP. D.,
BeverleyP. C.,
SattentauQ. J.1990; Novel anti-CD4 monoclonal antibodies separate human immunodeficiency virus infection and fusion of CD4+ cells from virus binding. Journal of Experimental Medicine 172:1233–1242
HoffmanA. D.,
BanapourB.,
LevyJ. A.1985; Characterization of the AIDS-associated retrovirus reverse transcriptase and optimal conditions for its detection in virions. Virology 147:326–335
JohnsonV. A.,
ByingtonR. E.1990; Infectivity assay (virus yield assay). In Techniques in HIV Research pp 71–76 Edited by
AldovaniA.,
WalkerB. D.
New York: Stockton Press;
KabatD.,
KozakS. L.,
WehrlyK.,
ChesebroB.1994; Differences in CD4 dependence for infectivity of laboratory-adapted and primary patient isolates of human immunodeficiency virus type 1. Journal of Virology 68:2570–2577
KalterD. C.,
GendelmanH. E.,
MeltzerM. S.1991; Inhibition of human immunodeficiency virus infection in monocytes by monoclonal antibodies against leukocyte adhesion molecules. Immunology Letters 30:219–228
KlasseP. J.,
MooreJ. P.,
JamesonB. A.1993; The interplay of the HIV-1 envelope complex, gp120 and gp41, with CD4. In HIV Molecular Organization. Pathogenicity and Treatment pp 241–266 Edited by
MorrowW. J. W.,
HaigwoodN. L.
Amsterdam: Elsevier Science Publishers;
KonopkaK.,
DavisB. R.,
LarsenC. E.,
AlfordD. R.,
DebsR. J.,
DüzgünesN.1990; Liposomes modulate human immunodeficiency virus infectivity. Journal of General Virology 71:2899–2907
KowalskiM.,
BergeronL.,
DorfmanT.,
HaseltineW.,
SodroskiJ.1991; Attenuation of human immunodeficiency virus type 1 cytopathic effect by a mutation affecting the transmembrane envelope glycoprotein. Journal of Virology 65:281–291
LarsenC. E.,
AlfordD. R.,
YoungL. J. T.,
McGrawT. P.,
DüzgünesN.1990; Fusion of simian immunodeficiency virus (SIVmac) with liposomes and erythrocyte ghosts: effect of liposome composition, low pH and calcium. Journal of General Virology 71:1947–1955
LifsonJ. D.,
HwangK. M.,
NaraP. L.,
FraserB.,
PadgettM.,
DunlopN. M.,
EidenL. E.1988; Synthetic CD4 peptide derivatives that inhibit HIV infection and cytopathicity. Science 241:712–716
LuS.,
PutneyS. D.,
RobinsonH. L.1992; Human immunodeficiency virus type 1 entry into T cells: more-rapid escape from an anti-V3 loop than from an antireceptor antibody. Journal of Virology 66:2547–2550
McDougalJ. S.,
NicholsonJ. K. A.,
CrossG. D.,
CortS. P.,
KennedyM. S.,
MawleA. C.1986; Binding of the human retrovirus HTLV-III/LAV/ARV/HIV to the CD4 (T4) molecule: conformation dependence, epitope mapping, antibody inhibition, and potential for idiotypic mimicry. Journal of Immunology 137:2937–2944
MooreJ. P.,
McKeatingJ. A.,
WeissR. A.,
ClaphamP. R.,
SattentauQ. J.1991; Receptor-mediated activation of immunodeficiency viruses in viral fusion. Science 252:1322–1323
MooreJ. P.,
SattentauQ. J.,
KlasseP. J.,
BurklyL. C.1992; A monoclonal antibody to CD4 domain 2 blocks soluble CD4-induced conformational changes in the envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1) and HIV-1 infection of CD4+ cells. Journal of Virology 66:4784–4793
OhkiK.,
KimuraT.,
OhmuraK.,
KatoS.,
IkutaK.1990; Blocking of HIV-1 infection, but not HIV-1-induced syncytium formation, by a CD4 peptide derivative partly corresponding to an immunoglobulin CDR3. AIDS 14:1160–1161
OhkiK.,
KimuraT.,
OhmuraK.,
MorikawaY.,
JonesI. M.,
AzumaI.,
IkutaK.1992; Monoclonal antibodies to a CD4 peptide derivative which includes the region corresponding to an immunoglobulin CDR3: evidence of the involvement of pre-CDR3-related region in HIV-1 and host cell interaction. Molecular Immunology 29:1391–1400
PantaleoG.,
PoliG.,
ButiniL.,
FoxC.,
DaytonA. I.,
FauciA. S.1991a; Dissociation between syncytia formation and HIV spreading. Suppression of syncytia formation does not necessarily reflect inhibition of HIV infection. European Journal of Immunology 21:1771–1774
PantaleoG.,
ButiniL.,
GraziosiC.,
PollG.,
SchnittmanS. M.,
GreenhouseJ. J.,
GallinJ. I.,
FauciS. A.1991b; Human immunodeficiency virus (HIV) infection in CD4+ T lymphocytes genetically deficient in LFA-1: LFA-1 is required for HIV-mediated cell fusion but not for viral transmission. Journal of Experimental Medicine 173:511–514
PoulinL.,
EvansL. A.,
TangS.,
BarbozaA.,
LeggH.,
LittmanD. R.,
LevyJ. A.1991; Several CD4 domains can play a role in human immunodeficiency virus infection of cells. Journal of Virology 65:4893–4901
RauschD. M.,
LifsonJ. D.,
PadgettM. P.,
ChandrasekharB.,
LendvayJ.,
HwangK. M.,
EidenL. E.1992; CD4 (81–92)-based peptide derivatives. Structural requirements for blockade of HIV infection, blockade of HIV-1 induced syncytium formation, and virostatic activity in vitro
. Biochemical Pharmacology 43:1785–1796
ReyF.,
DonkerG.,
HirschI.,
ChermannJ.-C.1991; Productive infection of CD4+ cells by selected HIV strains is not inhibited by anti-CD4 monoclonal antibodies. Virology 181:165–171
SatoH.,
OrensteinJ.,
DimitrovD.,
MartinM.1992; Cell-to-cell spread of HIV-1 occurs within minutes and may not involve the participation of virus particles. Virology 186:712–724
SattentauQ. J.,
MooreJ. P.1991; Conformational changes induced in the human immunodeficiency virus envelope glycoproteins by soluble CD4 binding. Journal of Experimental Medicine 174:407–415
SattentauQ. J.,
ArthosJ.,
DeenK.,
HannaN.,
HealeyD.,
BeverleyP. C. L.,
SweetR.,
TrunehA.1989; Structural analysis of the human immunodeficiency virus-binding domain of CD4. Journal of Experimental Medicine 170:1319–1334
ScholsD.,
PauwelsR.,
WitvrouwM.,
DesmyterJ.,
De ClercqE.1992; Differential activity of polyanionic compounds and castanospermine against HIV replication and HIV-induced syncytium formation depending on virus strain and cell type. Antiviral Chemistry and Chemotherapy 3:23–29
SinangilF.,
LoyterA.,
VolskyD. J.1988; Quantitative measurement of fusion between human immunodeficiency virus and cultured cells using membrane fluorescence dequenching. FEBS Letters 239:88–92
SodroskiJ.,
GohW. C.,
RosenC.,
CampbellK.,
HaseltineW.1986; Role of the HTLV-III/LAV envelope in syncytium formation and cytopathicity. Nature 322:470–474
SteffyK. R.,
KrausG.,
LooneyD. J.,
Wong-StaalF.1992; Role of fusogenic peptide sequence in syncytium induction and infectivity of human immunodeficiency virus type 2. Journal of Virology 66:4532–4535
SteinB. S.,
EnglemanE. G.1991; Mechanism of HIV-1 entry into CD4+ T cells. In Mechanisms and Specificity of HIV Entry into Host Cells pp 71–86 Edited by
DüzgünesN.
New York: Plenum Press.;
TersmetteM.,
De GoedeR. E. Y.,
AlB. J. M.,
WinkelI. N.,
GrutersR. A.,
CuypersH. T.,
HuismanH. G.,
MiedemaF.1989; Differential syncytium-inducing capacity of human immunodeficiency virus isolates: frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. Journal of Virology 62:2026–2032
TrunehA.,
BuckD.,
CassattD. R.,
JuszczakR.,
KassisS.,
RyuS.-E.,
HealeyD.,
SweetR.,
SattentauQ.1991; A region in domain 1 of CD4 distinct from the primary gp120 binding site is involved in HIV infection and virus-mediated fusion. Journal of Biological Chemistry 266:5942–5948